<DOC>
	<DOCNO>NCT02184741</DOCNO>
	<brief_summary>To estimate safety efficacy intravenous immunoglobulin therapy use GB-0998 woman four miscarriage carry randomize , placebo-controlled , double-blinded studyï¼Ž</brief_summary>
	<brief_title>Evaluation Safety Efficacy GB-0998 Unexplained Primary Recurrent Miscarriage</brief_title>
	<detailed_description />
	<mesh_term>Abortion , Spontaneous</mesh_term>
	<mesh_term>Abortion , Habitual</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>1 . Patients experience live birth . 2 . Patients four miscarriage . 3 . Patients obvious cause recurrent miscarriage , miscarriage even appropriate treatment . 1 . Patients abnormality karyotype analysis either patient partner . 2 . Patients diagnose antiphospholipid antibody syndrome accord international criterion . 3 . Patients receive appropriate treatment spite diagnosis diabetes impair glucose tolerance . 4 . Patients experience receive IVIg treatment recurrent miscarriage . 5 . Patients receive treatment malignancy . 6 . Patients history thromboembolism . 7 . Patients history shock hypersensitivity GB0998 . 8 . Patients hereditary fructose intolerance IgA deficiency .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>41 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>IVIG</keyword>
	<keyword>Unexplained Recurrent miscarriage</keyword>
	<keyword>Recurrent abortion</keyword>
	<keyword>Intravenous immunoglobulin</keyword>
</DOC>